TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

Key facts

Sponsor

Centers for Disease Control and Prevention

Principal Investigator

Marc Weiner, MD, M.D

Audie L. Murphy VA Medical Center, San Antonio TX

Intervention

Isoniazid(drug)

Enrollment

150 target

Eligibility

18 years · All sexes

Timeline

1999 – 2002

Study locations (23)

• Central Arkansas Veterans Health System, Little Rock, Arkansas, United States
• LA County/USC Medical Center, Los Angeles, California, United States
• University of California, San Francisco, San Francisco, California, United States
• Denver Department of Public Health and Hospitals, Denver, Colorado, United States
• Washington, D.C. VAMC, Washington D.C., District of Columbia, United States
• Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
• Hines VA Medical Center, Hines, Illinois, United States
• Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
• Boston Medical Center, Boston, Massachusetts, United States
• New Jersey Medical School, Newark, New Jersey, United States
• New York University School of Medicine, New York, New York, United States
• Columbia University/Presbyterian Medical Center, New York, New York, United States
• Harlem Hospital Center, New York, New York, United States
• Carolinas Medical Center, Charlotte, North Carolina, United States
• Duke University Medical Center, Durham, North Carolina, United States
• +8 more locations on ClinicalTrials.gov

Collaborators

US Department of Veterans Affairs

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05917210
  Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
  Yale University
• RECRUITINGNCT07312266
  Questioning the Epidemiology of Asymptomatic TB
  Barcelona Institute for Global Health
• RECRUITINGNANCT05842161
  South Africa Smoking Cessation and Engagement in HIV/TB Care Care
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT05575518
  A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
  Stellah Mpagama
• ACTIVE NOT RECRUITINGPHASE4NCT05118490
  Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
  The Aurum Institute NPC
• RECRUITINGNANCT05342064
  Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
  Baylor College of Medicine

See all trials for Primary genito-urinary tuberculosis →